- Global Operation
- Contract Manufacturing
Meropenem is a carbapenem antibiotic for parenteral use, that is stable to human dehydropeptidase-I (DHP-I). It is structurally similar to imipenem. Meropenem exerts its bactericidal action by interfering with vital bacterial cell wall synthesis. The ease with which it penetrates bacterial cells, its high level of stability to all serine b-lactamases and its marked affinity for the Penicillin Binding Proteins (PBPs) explain the potent bactericidal activity of Meropenem against a broad spectrum of aerobic and anaerobic bacteria. Meropenem is stable in susceptibility tests and these tests can be performed using the normal routine systems. In vitro tests show that Meropenem can act synergistically with various antibiotics. It has been demonstrated both in vitro and in vivo that Meropenem has a post-antibiotic effect against Gram-positive and Gram-negative organisms.
Neopenem® is indicated for treatment, in adults and children, of the following infections caused by single or multiple susceptible bacteria and as empiric therapy prior to the identification of the causative organisms:
Lower Respiratory Tract Infections
Urinary Tract Infections, including complicated infections
Gynaecological Infections, including postpartum infections
Skin and Skin Structure Infections
Empiric treatment, including initital monotherapy, for presumed bacterial infections in host-compromised, neutropenic patient
Because of its broad spectrum of bactericidal activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria, Neopenem® is effective for the treatment of polymicrobial infections.
Neopenem® 500 mg I.V Injection: Each combipack contains 1 vial of Meropenem 500 mg and 1 ampoule of 10 ml WFI.
Neopenem® 1 g I.V Injection: Each combipack contains 1 vial of Meropenem 1 g and 2 ampoules of 10 ml WFI.